GSK
NEWS
The UK’s exit from the European Union, Brexit, will impact numerous industries in the UK and Europe, but the biopharma industry has its own unique challenges.
When consumers have their genome tested by services like 23andMe and Ancestry.com, the companies hold the rights to the genetic information, which they often sell to biopharmaceutical companies. Nebula Genomics is taking a different approach.
Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software
Advancing proprietary pipeline; solid progress in partnered programs
What did Dr. Victor Frankenstein use to bring his “monster” to life? Electricity. And as much as that seemed far-fetched when Mary Shelley wrote the novel in 1818, the use of electrical devices and electricity to treat diseases has advanced significantly—and continues to advance.
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
Facilities in The Schrödinger Building to bring together AI experts and biologists
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
JOBS
IN THE PRESS